NORM-HF Pivotal Study
NCT: NCT07574593 · NOT_YET_RECRUITING
Brief Summary
This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF events and cardiovascular mortality compared to standard of care treatment. Patients will be randomized in a 1:1 ratio to receive either NORM™ System and guided heart failure management (intervention group) or usual standard of care with guided heart failure management (control group).
Frequently Asked Questions
What is NORM-HF Pivotal Study?
NORM-HF Pivotal Study is a clinical trial registered under NCT07574593. Current status: NOT_YET_RECRUITING.
What is the status of NCT07574593?
The current status of NCT07574593 (NORM-HF Pivotal Study) is: NOT_YET_RECRUITING.
When did NORM-HF Pivotal Study start?
NORM-HF Pivotal Study started on 2026-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.